Management of Immune-Related Colitis During the COVID-19 Pandemic

Inflamm Bowel Dis. 2020 Sep 18;26(10):e110-e111. doi: 10.1093/ibd/izaa235.

Authors

Rajan Amin¹, Anusha S Thomas², Shruti Khurana¹, Kavea Panneerselvam³, Fangwen Zou², Weijie Ma², Suresh T Chari², Yinghong Wang²

Affiliations

¹ Department of Internal Medicine, The University of Texas, Health Science Center, Houston, Texas, USA.
² Department of Gastroenterology, Hepatology and Nutrition, The University of MD Anderson Cancer Center, Houston, Texas, USA.
³ Department of Internal Medicine, Baylor College of Medicine, Houston, Texas, USA.

No abstract available

Keywords: COVID-19; cancer; immune checkpoint inhibitor; immune-related colitis.

Publication types

Letter

MeSH terms

Betacoronavirus
COVID-19
Colitis* / etiology
Colitis* / immunology
Colitis* / therapy
Communicable Disease Control / methods*
Coronavirus Infections* / diagnosis
Coronavirus Infections* / epidemiology
Coronavirus Infections* / prevention & control
Humans
Immunocompromised Host
Immunosuppressive Agents* / administration & dosage
Immunosuppressive Agents* / adverse effects
Neoplasm Staging
Neoplasms / pathology
Neoplasms / therapy*
Pandemics* / prevention & control
Patient Care Management / methods*
Pneumonia, Viral* / diagnosis
Pneumonia, Viral* / epidemiology
Pneumonia, Viral* / prevention & control
SARS-CoV-2

Substances

Immunosuppressive Agents